Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment (Feb, 10.1038/s41423-023-00983-5, 2023)

被引：3

作者：

Yang, Xue

Li, Qing

Liu, Wenting

Zong, Chen

Wei, Lixin

Shi, Yufang

Han, Zhipeng

机构：

[1] Department of Tumor Immunology and Gene Therapy Center, Third Affiliated Hospital of Naval Medical University, Shanghai

[2] Key Laboratory on Signaling Regulation and Targeting Therapy of Liver Cancer, Ministry of Education, Eastern Hepatobiliary Surgery Hospital/National Center for Liver Cancer, Naval Medical University, Shanghai

[3] The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, State Key Laboratory of Radiation Medicine and Protection, Key Laboratory of Stem Cells and Medical Biomaterials of Jiangsu Province, Medical College of Soochow Uni

[4] Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome

[5] CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai

来源：

CELLULAR & MOLECULAR IMMUNOLOGY | 2023年 / 20卷 / 06期

基金：

中国国家自然科学基金; 国家重点研发计划;

关键词：

Clinical application; Hepatic fibrosis/cirrhosis; Mesenchymal stromal cells; Pathogenesis; Treatment;

D O I：

10.1038/s41423-023-01010-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Hepatic fibrosis/cirrhosis is a significant health burden worldwide, resulting in liver failure or hepatocellular carcinoma (HCC) and accounting for many deaths each year. The pathogenesis of hepatic fibrosis/cirrhosis is very complex, which makes treatment challenging. Endogenous mesenchymal stromal cells (MSCs) have been shown to play pivotal roles in the pathogenesis of hepatic fibrosis. Paradoxically, exogenous MSCs have also been used in clinical trials for liver cirrhosis, and their effectiveness has been observed in most completed clinical trials. There are still many issues to be resolved to promote the use of MSCs in the clinic in the future. In this review, we will examine the controversial role of MSCs in the pathogenesis and treatment of hepatic fibrosis/cirrhosis. We also investigated the clinical trials involving MSCs in liver cirrhosis, summarized the parameters that need to be standardized, and discussed how to promote the use of MSCs from a clinical perspective. © 2023, The Author(s), under exclusive licence to CSI and USTC.

引用

页码：687 / 688

页数：2

共 1 条

[1] Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment (Feb, 10.1038/s41423-023-00983-5, 2023) [J].

Yang, Xue ;

Li, Qing ;

Liu, Wenting ;

Zong, Chen ;

Wei, Lixin ;

Shi, Yufang ;

Han, Zhipeng .

CELLULAR & MOLECULAR IMMUNOLOGY, 2023, 20 (06) :687-688

← 1 →